{
    "clinical_study": {
        "@rank": "147879", 
        "arm_group": {
            "arm_group_label": "KX2-391 and Paclitaxel", 
            "arm_group_type": "Experimental", 
            "description": "The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. 3 or 6 subjects with solid tumor per dose group will likely be necessary to determine the MTD of KX2-391 in combination with weekly paclitaxel. With paclitaxel dose fixed at 80 mg/m2/weekly, KX2-391 treatment will be started at 20 mg dose once daily (QD)\nThe phase II portion of this trial has a design to determine the efficacy of KX2-391 when administered in combination with paclitaxel in 20 subjects with stomach cancer and 20 subjects with breast cancer"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this study is to determine the maximum tolerated dose (MTD) of\n      KX2-391 in Combination with paclitaxel in Phase I, and to evaluate the efficacy of KX2-391\n      in combination with paclitaxel in patients who are diagnosed as gastric and breast cancer,\n      respectively in Phase II."
        }, 
        "brief_title": "A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Unspecified Adult Solid Tumor, Protocol Specific", 
            "Gastric Cancer", 
            "Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Stomach Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Phase I Portion:\n\n        - Diagnosis of solid tumors on histopathological examination or cytological examination\n        for which no standard of care is available or conventional treatment modalities have no\n        therapeutic effect at the time of entering into the study\n\n        Phase II Portion:\n\n          -  Diagnosis of advanced/metastatic/recurrent stomach cancer or breast cancer on\n             histopathological examination or cytological examination for which no standard of\n             care is available or conventional treatment modalities have no therapeutic effect at\n             the time of entering into the study\n\n          -  Subjects with stomach cancer without prior taxane therapy\n\n          -  Subjects with breast cancer with prior taxane therapy\n\n          -  (Optional) Providing exploratory biomarker informed consent form to obtain archival\n             tumor tissue and/or new tumor biopsy sample\n\n        Common:\n\n          1. Based on clinical screening,\n\n             \u2460 If radiotherapy was given, at least 4 weeks should have passed from the last\n             treatment date and the patient should have recovered from the toxicity (However, for\n             limited regional radiotherapy, at least 2 weeks from the last treatment date)\n\n             \u2461 If hormonal therapy was given, at least 2 weeks should have passed from the last\n             treatment date and the patient should have recovered from the toxicity.\n\n             \u2462 If chemotherapy was given, at least 3 weeks should have passed from the last\n             treatment date and the patient should have recovered from the toxicity (However, for\n             nitrosourea or mitomycin, at least 6 weeks)\n\n          2. Aged \u2265 20 years\n\n          3. ECOG (Eastern Cooperative Oncology Group) \u2264 2\n\n          4. Life expectancy \u2265 12 weeks\n\n          5. Should meet the followings,\n\n             \u2460 Bone marrow function ANC (Absolute Neutrophil Count) \u2265 1.5 X 109/L, PLT (Platelet\n             Count) \u2265 100 X 109/L, Hemoglobin \u2265 9.0 g/dl (In the case of hemoglobin of < 9.0 g/dl,\n             the patient can be enrolled if the value is reversed to \u2265 9.0 g/dl.)\n\n             \u2461 Kidney function Creatinine Clearance > 50 ml/min or Serum Clearance \u2264 1.5 mg/dl\n\n             \u2462 Liver function AST (Aspartate Aminotransferase)/ALT (Alanine Aminotransferase)/ALP\n             (Alkaline Phosphatase) \u2264 3.0 X UNL and Total bilirubin \u2264 2.0 mg/dl (With bone\n             metastasis, ALP \u2264 5.0 X UNL)\n\n          6. At least one measurable lesions with the length of the longest diameter of \u2265 10 mm on\n             spiral CT or multidetector CT or \u2265 20 mm on conventional CT\n\n          7. Subjects who voluntarily consent to participate in this study and sign the written\n             informed consent form\n\n        Exclusion Criteria:\n\n          1. Uncontrolled central nervous system metastasis\n\n          2. Malignant ascites requiring surgical treatment\n\n          3. Subjects who have blood malignancies including leukemia; or who have received or will\n             receive bone marrow transplantation\n\n          4. Severe concurrent diseases as follows,\n\n             \u2460 History of unstable angina, heart failure, atrial or ventricular arrhythmia\n             requiring pharmacological treatment, or having received treatment for myocardial\n             infarction within 6 months (however, may be included under the judgment of the\n             investigator if medically controlled), heart failure of Class III or IV by New York\n             Heart Association Classes, or left ventricular ejection fraction of < 40%\n\n             \u2461 Receiving therapeutic dose administration of coumarin-type anticoagulants (however,\n             up to 2 mg daily is permitted for line opening)\n\n             \u2462 Uncontrolled diabetes (fasting plasma glucose > 2.0 X UNL), severe hypertension,\n             thyroid disorder and active infectious disease\n\n             \u2463 Psychiatric or neurological history including dementia or epilepsy which may\n             threaten the compliance with this protocol\n\n             \u2464 A condition not allowing oral application of tablet formulation, and any clinically\n             significant gastrointestinal abnormalities which may interfere with taking, passing\n             or absorption of the study drug\n\n          5. Using disallowed concomitant medications (strong CYP3A4 (Cytochrome P450 3A4)\n             inhibitors or inducers) (When a patient is using any of the disallowed concomitant\n             medications below, wash-out of 1 week from the medication date is required)\n\n          6. Received other investigational product within 4 weeks prior to the administration of\n             this study drug\n\n          7. Pregnant or breast-feeding women (however, women with 12 months of natural\n             (spontaneous) amenorrhea or surgical bilateral oophorectomy (alone or with\n             hysterectomy) at least 6 weeks ago, with appropriate clinical profile (e.g.,\n             appropriate age, history of vasomotor symptoms), will be considered women\n             postmenopausal and of non-childbearing potential. In the case of oophorectomy alone,\n             a woman will be considered to be of non-childbearing potential only if her\n             reproductive condition is confirmed by follow-up hormone level assessment)\n\n          8. History of hypersensitivity to paclitaxel, compounds with similar chemical structure,\n             or cremophor (polyoxyethylated castor oil) ingredient\n\n          9. Neuropathy of grade \u2265 3 based on clinical screening\n\n         10. Known history of hepatitis B or C and known history of HIV serum positive\n\n         11. Others unable to participate in the study under the judgment of the investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01764087", 
            "org_study_id": "HM-KXI-101", 
            "secondary_id": "2156"
        }, 
        "intervention": {
            "arm_group_label": "KX2-391 and Paclitaxel", 
            "description": "A treatment cycle in phase I will consist of 28 days, according to the following schedule:\nKX2-391 20 mg PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.\nThe trial will initially test the combination of weekly paclitaxel and KX2-391 given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort, this intervention will be terminated\nA treatment cycle in phase II will consist of 28 days, according to the following schedule:\nKX2-391 MTD PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.", 
            "intervention_name": "KX2-391 and Paclitaxel", 
            "intervention_type": "Drug", 
            "other_name": [
                "KX01", 
                "Taxol"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Paclitaxel", 
                "Protein Kinase Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Stomach Neoplasms", 
            "Breast Neoplasms", 
            "Carcinoma", 
            "Neoplasms", 
            "Paclitaxel", 
            "Tubulin Modulators", 
            "Antimitotic Agents", 
            "Protein Kinase Inhibitors", 
            "Enzyme Inhibitors", 
            "Pharmacologic Actions"
        ], 
        "lastchanged_date": "January 7, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Yun Jin Kim", 
                    "phone": "+82-31-787-1421"
                }, 
                "facility": {
                    "address": {
                        "city": "Seongnam", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-Do", 
                        "zip": "463-707"
                    }, 
                    "name": "Seoul National University Bundang Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eunkyung Kim", 
                    "phone": "+82-2-2072-7616"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "110-744"
                    }, 
                    "name": "Seoul National University Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Phase I/II Study of KX2-391 in Combination With Paclitaxel in Patients With Advanced Solid Tumors", 
        "other_outcome": [
            {
                "description": "Pre-dose and post-dose tubulin inhibition in peripheral blood monocytes extracted from blood samples, as measured by immunofluorescence staining", 
                "measure": "Pharmacodynamic (PD) Evaluation in Phase I Portion", 
                "safety_issue": "No", 
                "time_frame": "Time points at day 0 and 1 in cycle 1"
            }, 
            {
                "description": "Pre-dose and post-dose Src signaling inhibition (p-Src and Ki-67) in archival tumor tissue and new biopsy sample, as measured by immunohistochemistry", 
                "measure": "Exploratory Biomarker Evaluation in Phase II Portion", 
                "safety_issue": "No", 
                "time_frame": "Time points at day -6 and day 0"
            }
        ], 
        "overall_contact": {
            "last_name": "Seock-Ah Im, M.D., Ph.D.", 
            "phone": "+82-2-2072-0850"
        }, 
        "overall_contact_backup": {
            "last_name": "Jee Hyun Kim, M.D., Ph.D.", 
            "phone": "+82-31-713-5132"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Seock-Ah Im, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Maximum tolerated dose (MTD) of KX2-391 in combination with weekly paclitaxel as determined by number of participants With DLTs related to KX2-391 in combination with weekly paclitaxel", 
                "measure": "Dose-limiting Toxicities (DLTs) in Phase I Portion", 
                "safety_issue": "Yes", 
                "time_frame": "From start of the treatment to end of cycle 1, which are 4 weeks"
            }, 
            {
                "description": "The efficacy (overall response rate; ORR; complete response (CR) + partial response (PR)) of KX2-391 in combination with weekly paclitaxel at the MTD established during the phase I portion of this trial based on RECIST (Response Evaluation Criteria in Solid Tumor) 1.1", 
                "measure": "Tumor Overall Response Rates (ORRs) in Phase II Portion", 
                "safety_issue": "No", 
                "time_frame": "In every 2 cycles up to end of the treatment, an expected average of 16 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01764087"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PK parameters, including but not limited to, plasma concentration, AUC (Area Under Curve) 0-t, Cmax, Tmax, and T1/2 of KX2-391 alone and in combination with weekly paclitaxel", 
                "measure": "Pharmacokinetic (PK) Evaluation in Phase I Portion", 
                "safety_issue": "No", 
                "time_frame": "Time points at day 0, 1 and 8 in cycle 1"
            }, 
            {
                "description": "The preliminary efficacy of KX2-391 in combination with weekly paclitaxel as determined by ORRs based on RECIST 1.1", 
                "measure": "The Preliminary Efficacy Data in Phase I Portion", 
                "safety_issue": "No", 
                "time_frame": "In every 2 cycles up to end of the treatment, an expected average of 8 weeks"
            }, 
            {
                "description": "Adverse events and their frequency, duration and severity, physical examination, laboratory parameters, vital signs and ECG change monitoring as determined based on CTCAE (Common Toxicity Criteria for Adverse Effects) 4.03", 
                "measure": "Safety in Phase II Portion", 
                "safety_issue": "Yes", 
                "time_frame": "From start of the treatment to end of the treatment, an expected average of 16 weeks"
            }, 
            {
                "description": "Overall survival (OS), progression free survival (PFS), time to tumor progression (TTP) and duration of response", 
                "measure": "The Efficacy Data in Phase II Portion", 
                "safety_issue": "No", 
                "time_frame": "Up to die, an expected average of 24 weeks"
            }, 
            {
                "description": "PK parameters, including but not limited to, plasma concentration, AUC0-t, Cmax, Tmax, and T1/2 of KX2-391 alone and in combination with weekly paclitaxel", 
                "measure": "Pharmacokinetic (PK) Evaluation in Phase II Portion", 
                "safety_issue": "No", 
                "time_frame": "Time points at day 1 and 8 in cycle 1"
            }
        ], 
        "source": "Hanmi Pharmaceutical Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}